Omlonti FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 28, 2022.
FDA Approved: Yes (First approved September 22, 2022)
Brand name: Omlonti
Generic name: omidenepag isopropyl
Dosage form: Ophthalmic Solution
Company: Santen Inc.
Treatment for: Glaucoma/Intraocular Hypertension
Omlonti (omidenepag isopropyl) is a relatively selective prostaglandin E2 (EP2) receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Omlonti is thought to reduce elevated intraocular pressure by increasing aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways.
- Omlonti is administered into the affected eye(s) once daily in the evening.
- Warnings and precautions associated with Omlonti include pigmentation, eyelash changes, ocular inflammation, and macular edema.
- Common adverse reactions include conjunctival hyperemia, photophobia, blurred vision, dry eye, instillation site pain, eye pain, ocular hyperemia, punctate keratitis, headache, eye irritation, and visual impairment.
Development timeline for Omlonti
| Date | Article |
|---|---|
| Sep 26, 2022 | Approval FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
